Evidence map›Paper›PMID 38616571›Full record

ArticleAddiction (Abingdon, England)2024

Empirically contrasting urine drug screening-based opioid use disorder treatment outcome definitions.

Laura Brandt, Gabriel J Odom, Mei-Chen Hu, Clinton Castro, Raymond R Balise, CTN‐0094 Team

Abstract read
In one paragraph

Article in Addiction (Abingdon, England), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Laura BrandtDepartment of Psychology, The City College of New York, New York, New York, USA.ORCID 0000-0001-7551-221X
Gabriel J OdomDepartment of Biostatistics, Florida International University, Miami, Florida, USA.
Mei-Chen HuDepartment of Psychiatry, Columbia University Irving Medical Center, New York, New York, USA.
Clinton CastroThe Information School, University of Wisconsin-Madison, Madison, Wisconsin, USA.
Raymond R BaliseDivision of Biostatistics, Department of Public Health Sciences, The University of Miami, Miami, Florida, USA.
CTN‐0094 Team

Funding

Project-003UG1DA013035 · NIDA · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI Aimee N Campbell, Jennifer McNeely · 2015 to 2026
$130.3M
NIDA NIH HHS UG1 DA013035NIDA NIH HHS UG1DA013035-17NIMHD NIH HHS FIU-RCMI Pilot AWD000000009108
6 · The paper itself

Abstract

BACKGROUND AND

aimsA lack of consensus on the optimal outcome measures to assess opioid use disorder (OUD) treatment efficacy and their precise definition and computation has hampered the pooling of research data for evidence synthesis and meta-analyses. This study aimed to empirically contrast multiple clinical trial definitions of treatment success by applying them to the same dataset.

methodsData analysis used a suite of functions, developed as a software package for the R language, to operationalize 61 treatment outcome definitions based on urine drug screening (UDS) results. Outcome definitions were derived from clinical trials that are among the most influential in the OUD treatment field. Outcome functions were applied to a harmonized dataset from three large-scale National Drug Abuse Treatment Clinical Trials Network (CTN) studies, which tested various medication for OUD (MOUD) options (n = 2492). Hierarchical clustering was employed to empirically contrast outcome definitions.

resultsThe optimal number of clusters identified was three. Cluster 1, comprising eight definitions focused on detecting opioid-positive UDS, did not include missing UDS in outcome calculations, potentially resulting in inflated rates of treatment success. Cluster 2, with the highest variability, included 10 definitions characterized by strict criteria for treatment success, relying heavily on UDS results from either a brief period or a single study visit. The 43 definitions in Cluster 3 represented a diverse range of outcomes, conceptualized as measuring abstinence, use reduction and relapse. These definitions potentially offer more balanced measures of treatment success or failure, as they avoid the extreme methodologies characteristic of Clusters 1 and 2.

conclusionsClinical trials using urine drug screening (UDS) for objective substance use assessment in outcome definitions should consider (1) incorporating missing UDS data in outcome computation and (2) avoiding over-reliance on UDS data confined to a short time frame or the occurrence of a single positive urine test following a period of abstinence.

Indexed as

Opioid-Related DisordersSubstance Abuse DetectionCluster AnalysisHumansOpiate Substitution TreatmentOutcome Assessment, Health CareTreatment Outcomeabstinenceclinical trialopioid use disorderoutcomerelapsetreatmenturine drug screen

Identifiers

PMID38616571
PMCPMC12165254

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.